TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05720182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compremium Compressibility Measurement
Description: CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~* Place the probe on the target area~* Identify correct landmark~* Compress the compartment~* Increase steadily the pressure applied by the CP probe to 80 mmHg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill Running
Description: Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements.
Study: NCT03988400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Augmentation
Description: Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random Vibration
Description: Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
Study: NCT05139680

Intervention type: DRUG
Intervention: tafamidis
Description: 80 or 61 milligrams (mg)
Study: NCT04696692

Intervention type: OTHER
Group type: OTHER
Intervention: Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
Description: Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision.
Study: NCT06510660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab
Description: The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab
Description: The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
Study: NCT05141383

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Description: A blood sample and a urine sample after prostate massage will be carried out at baseline

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Description: A blood sample and a urine sample after prostate massage will be carried out at baseline

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Description: A blood sample and a urine sample after prostate massage will be carried out at baseline
Study: NCT06419270

Intervention type: OTHER
Intervention: Observation
Description: Observational

Intervention type: OTHER
Intervention: Observation
Description: Observational
Study: NCT06512064

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE testing to estimate lung function and aid in disease diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE testing to estimate lung function and aid in disease diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE testing to estimate lung function and aid in disease diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE testing to estimate lung function and aid in disease diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE testing to estimate lung function and aid in disease diagnosis
Study: NCT06184633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3.2 MG/ML
Description: Intervention arm receives semaglutide in addition to combined lifestyle intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm receives placebo in addition to combined lifestyle intervention
Study: NCT05407441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol
Study: NCT04768504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Tofacitinib 10 mg PO BID for 30 days
Study: NCT03955198

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy + durvalumab
Description: Radiotherapy will be administered in combination with Durvalumab
Study: NCT05917626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital SPA
Description: A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
Study: NCT05948735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT) for Preventing Falls
Description: The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates OEP-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Exercise (PTE) only for Preventing Falls
Description: The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
Study: NCT06493760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: VEGF antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Folinate
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: chemotherapy
Study: NCT05537753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encore PFO closure device
Description: The Encore PFO closure device comprises an implant component and a single-use delivery system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA-approved PFO closure device
Description: Chosen by the investigator
Study: NCT06220721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine ER
Description: Initiation of nifedipine ER postpartum at SBP ≥140 mmHg or DBP ≥90 mmHg and maintaining BP \<140/90 mmHg during the first 6 weeks postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine ER
Description: Initiation of nifedipine ER postpartum at SBP ≥140 mmHg or DBP ≥90 mmHg and maintaining BP \<140/90 mmHg during the first 6 weeks postpartum.
Study: NCT04991649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based Asthma Management Training Program
Description: In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual Group
Description: Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
Study: NCT05954858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Description: Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
Study: NCT04843566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal MRI-guided prostate biopsy
Description: Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal MRI-guided prostate biopsy
Description: Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (prophylaxis)
Description: For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Study: NCT05889156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NST-1024
Description: 400 mg BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo to active arm
Study: NCT05906953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG004
Description: Low dose Medium dose High dose
Study: NCT04664517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible intramedullary nail (FIN)
Description: Both bone FIN

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible intramedullary nail (FIN)
Description: Both bone FIN

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction auder general anesthesia and long arm cast
Description: Reduction and cast

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reduction auder general anesthesia and long arm cast
Description: Reduction and cast
Study: NCT06431048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.
Description: Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.
Description: Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.
Description: Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.
Description: Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).
Study: NCT05031819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.
Description: * TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~* Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.
Description: * TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~* Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH
Study: NCT05773937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Study: NCT05153746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D colonoscopy
Description: 3D colonoscopy is a new device to enhance endoscopic imaging.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D colonoscopy
Description: 3D colonoscopy is a new device to enhance endoscopic imaging.
Study: NCT05159830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral oil
Description: The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral oil
Description: Placebo of similar cannabidiol galenic form
Study: NCT06480747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Participants will strength train via linear periodization resistance exercise training.
Study: NCT05699642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi + wearable
Description: The tai chi intervention will be delivered remotely via Zoom Enterprise. Participants will access classes on a phone, tablet, laptop, or desktop computer. Participants will attend 3 classes/week (each lasting 60 min) during weeks 1-12, 2 classes/week during weeks 13-16, and then 1 class every other week during weeks 17-24. Classes include tai chi warm-up exercises, breathing exercises, review and practice of tai chi forms, and cool-down exercises. Participants will be asked to practice tai chi at home 3x per week during the 6 month intervention period using an instructional video provided to them. The Fitbit fitness tracker will be given to each participant along with instructions on how to use the tracker and the Fitbit app on their personal device.